This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

KTE-C19

Kite Pharma, Inc.

Drug Names(s): CD19 eACT CAR-T Therapy, Engineered Autologous Cell Therapy

Description: The Engineered Autologous Cell Therapy (eACT) Platform utilizes patients’ peripheral blood T lymphocytes genetically engineered with either chimeric antigen receptors (CAR) or T cell receptors (TCR) that recognize tumor-specific molecules, traffic directly to the tumor, become activated upon engagement with the tumor antigen, and selectively eradicate tumors.


KTE-C19 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug